1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-4, NCT00243646
|
|
2.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 38
Sponsor: Other
Protocol IDs: 1-whyte, NCT00380406
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0819, NCT00388804
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90203, NCT00430183
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_3503, EudraCT#:2007-000323-17, NCT00514917
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MRC-RADICALS-PR10, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: CAN-NCIC-PR12, PR12, NCT00651326
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 80 and under
Sponsor: Other
Protocol IDs: EORTC-22043-30041, EORTC-22043–30041, EU-20950, EUDRACT-2006-002772-17, NCT00949962
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0815, RTOG 0815, NCT00936390
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS37, RISPSA, NCT00928434
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UNC-LCCC-0420, LCCC 0420, NCT00225420
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 4P-06-3, NCT00669162
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB# 004-08, SR06-959, NCT00924807
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MUSC-031218, 100822, MUSC-HR-11357, NCT00103376
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: over 21
Sponsor: Other
Protocol IDs: 30296-A, L-8863, 06-2040-A-02, NCT00223665
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14954A, 7659, NCT00454571
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: DOCET-L-01892, NCT00452556
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0621, RTOG 0621, NCT00528866
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-05190, 05190, NCT00544830
|
|
20.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06160, 06-160, MSKCC IRB 06-160, 7864, NCT00589472
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-004, NCT00658697
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E3806, E3806, NCT00771017
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-190, NCT00776594
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HOG GU07-124, NCT00860158
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-280, NCT00903162
|
